What is Signostics?
Signostics is a company operating within the medical technology sector, focusing on point-of-care ultrasound technology and intelligent medical tools. Their primary objective is to enhance the daily operations of healthcare professionals through innovative solutions. The company's flagship product, the Kosmos Bladder scanner, leverages advanced AI technology to ensure high accuracy and reliability in bladder assessments. Signostics also provides a portfolio of portable ultrasound devices tailored for diverse medical fields, including cardiology, emergency medicine, and musculoskeletal imaging. By prioritizing affordability and user-centric design, Signostics aims to transform patient care by making advanced ultrasound capabilities more accessible.
How much funding has Signostics raised?
Signostics has raised a total of $44M across 3 funding rounds:
Series A
$4M
Series B
$5M
Private Equity
$35M
Series A (2009): $4M with participation from Terra Rossa Capital, Playford Capital, and Brandon Capital Partners
Series B (2010): $5M led by Terra Rossa Capital, Playford Capital, and Brandon Capital Partners
Private Equity (2015): $35M supported by KKR & Co. L.P.
Key Investors in Signostics
KKR & Co. L.P.
KKR is a global investment firm with a broad reach across various asset classes. They focus on fortifying companies and communities, aiming for shared success with their clients and portfolio companies.
Terra Rossa Capital
Terra Rossa Capital specializes in offering premium domain names, emphasizing secure transactions and the value of memorable online assets to enhance brand credibility.
Playford Capital
Playford Capital provides investment management with a team experienced in growing technology businesses, offering expertise in product development, international distribution, and capital raising.
What's next for Signostics?
The substantial enterprise-level funding secured by Signostics, totaling $44M, signals a pivotal phase of expansion and development for the company. This significant capital injection, particularly the recent major strategic investment of $35M, is poised to fuel innovation, scale operations, and potentially explore new market segments. The company is likely to focus on enhancing its AI-driven diagnostic tools and expanding the reach of its portable ultrasound solutions. Strategic partnerships and further technological advancements are anticipated as Signostics leverages this financing to solidify its position as a leader in accessible, intelligent medical imaging.
See full Signostics company page
